Melanoma/Skin Cancer News

The FDA announced several regulatory actions the past few weeks.

The addition of all-trans retinoic acid to pembrolizumab conferred benefit to patients with metastatic melanoma, according to results of a phase 1b/phase 2 trial published in Clinical Cancer Research.

Richard D. Carvajal, MD, has been appointed deputy physician-in-chief and director of medical oncology at Northwell Health Cancer Institute.

Maureen E. Murphy, PhD, has been appointed deputy director of Ellen and Ronald Caplan Cancer Center at The Wistar Institute.

In a scientific statement, the American Heart Association issued guidance on the epidemiology, diagnosis and management of cancer therapy-induced hypertension.

Despite more frequent poor prognostic factors, melanoma of unknown primary etiology was not associated with poorer survival than melanoma of known cutaneous etiology, according to a study.

Healio will present its second annual Disruptive Innovators Awards for oncology/hematology this spring.

Adolescents and young adults with stage IV melanoma experienced significantly lower survival rates compared with older adults, according to a study.

Researchers at Massachusetts General Hospital and Harvard Medical School have developed machine learning-based methods to predict which patients with early-stage melanoma have the highest risk for disease recurrence.

Response rates to investigational therapies evaluated in NCI-sponsored phase 1 trials for solid cancers have doubled over the past 2 decades, according to study results published in The Lancet.